Incretin hormones - an update
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Incretin hormones are insulinotropic hormones from the intestinal mucosa, which after being released in response to ingestion of a meal, enhance insulin secretion in excess of that elicited by the absorbed nutrients (glucose. amino acids etc) themselves. To day it is well established that the most important incretin hormones are glucose-dependent insulinotropic polypeptide (GIP, previously known as gastric inhibitory polypeptide) and glucagon-like peptide-1 (GLP-1) from the upper and lower small intestinal mucosa, respectively. It has been shown that interference with the incretin function causes glucose intolerance and it has also been shown that the incretin function is greatly impaired in type 2 diabetes mellitus. The reason for this seems to be twofold: an impaired secretion of GLP-1 and a severely impaired insulinotropic effect of GIP in these patients. In agreement with this, administration of the active incretin, GLP-1, to patients with type 2 diabetes may nearly normalise their fasting and postprandial hyperglycaemia. In addition to its insulinotropic effects, GLP-1 has been shown to stimulate the formation of new beta cells in rodents, partly by enhanced beta cell proliferation and partly by enhancing differentiation of duct progenitor cells to mature beta cells. GLP-1 also inhibits glucagon secretion, inhibits gastric emptying and reduces appetite and food intake. During the last years, therefore, several most promising attempts have been made to develop GLP-1 into a clinically useful therapeutic agent for the treatment of type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationPlasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Self-citationNew Interpretation of Oral Glucose Tolerance
Mcintyre, N., Holdsworth, C. D., & Turner, D. S. (1964) · The Lancet · doi:10.1016/s0140-6736(64)90011-x · Cited by 738
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Cited by
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120
Hirasawa, A., Tsumaya, K., Awaji, T., Katsuma, S., Adachi, T., Yamada, M., Sugimoto, Y., Miyazaki, S., & Tsujimoto, G. (2005) · Nature Medicine · doi:10.1038/nm1168 · Cited by 1,545
Edfalk, S., Steneberg, P., & Edlund, H. (2008) · Diabetes · doi:10.2337/db08-0307 · Cited by 587
“This so-called incretin effect is evident when comparing oral and intravenous or intraperitoneal administration of glucose; oral glucose administration triggers a more robust insulin secretory response (19).”
BackgroundThe incretin system and its role in type 2 diabetes mellitus
HOLST, J., VILSBOLL, T., & DEACON, C. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 515
Nilsson, M., Stenberg, M., Frid, A. H., Holst, J. J., & Björck, I. M. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.5.1246 · Cited by 473
Metadata
- Authors
- Ørskov, J. J. H.
- Venue
- Scandinavian Journal of Clinical and Laboratory Investigation
- Publisher
- Informa UK Limited
- Published
- 2001-01
- Volume
- 61
- Issue
- 234
- Pages
- 75-85
- ISSN
- 0036-5513 (ISSN-L)
- 1502-7686
- OpenAlex
- W2096872771
- Cited by
- 71
- References
- 20
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incretin hormones - an update. https://app.cochat.ai/papers/10.1080/clb.61.234.75.85
- The paper
- Ørskov, J. J. H. (2001). Incretin hormones - an update. Scandinavian Journal of Clinical and Laboratory Investigation. https://doi.org/10.1080/clb.61.234.75.85
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.